Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by bionicjoeon May 12, 2019 7:48am
98 Views
Post# 29738780

RE:2.6 Million required for initial treatment of Canadian patie

RE:2.6 Million required for initial treatment of Canadian patieFloatinketucky, you have too much time on your hands.

And you must stop insinuating that TLT has direct access to the $4.5M government grant. It is not their money to use and you know it. You can't imput it to calculate patient cost.

I'm glad at least that you don't try to read something that wasn't there anymore in the calling off of the original shelf prospectus. The fact that announcement was made by the OSC should have given you a hint that it had to do with something technical in nature.

Bottom line, investors should have seen a double by now to act as a safety chute given the information on the phase 1b study that has been released. Posters keep telling investors to just wait until the next catalyst and then you can take the double to the bank. It's going on 6 years of catalysts and still no double. Maybe you can spend some of your abundant free time answering that question.
Bullboard Posts